Skip to main content
OpenTrials
Completed

NCT Number: NCT01603277

Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids

This study will evaluate the safety, tolerability and efficacy of a single dose level of KB003 in subjects with inadequately controlled asthma.

Completed

Looking for future studies?

Notify Me

Key information

Age range

16 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Cairns, Queensland, Australia

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • A diagnosis of asthma established for at least 2 years
  • Symptomatic asthma as defined by the Juniper Asthma Control Questionnaire
  • Symptomatic asthma despite stable treatment with inhaled corticosteroids fluticasone or budesonide, or other corticosteroids, for at least 12 weeks
  • Currently receiving inhaled long-acting beta agonist (LABA) or previously documented LABA intolerability or lack of responsiveness
  • At least 2 exacerbations (no more than 6) in the previous 12 months that required systemic corticosteroids or at least a doubling of daily oral dose

Key Exclusion Criteria:

  • Acute asthma worsening (requiring emergency room visit, hospitalization, urgent care, physician visit, or change in asthma medications) or lower respiratory tract infection requiring the use of antibiotics, within 4 weeks prior to Screening Visit.
  • History of life-threatening asthma with admission to the intensive care unit requiring the use of mechanical ventilation within the past 12 months
  • Use of any immunosuppressive or immunomodulatory agents within 12 weeks or an investigational agent within 4 weeks prior to Screening Visit
  • History of any cardiovascular, neurological, hepatic, or renal condition
  • History of smoking within the past 12 months

Treatment and study plan

Anti-GM-CSF Monoclonal Antibody 400mg

Biological

Anti-GM-CSF Monoclonal Antibody 400mg

Placebo

Other

Normal Saline

Primary outcomes

  1. Change in Percent Predicted FEV1 at Week 24

    Time frame: Baseline to Week 24

Secondary outcomes

  1. To Evaluate the Efficacy of KB003 as Measured by Asthma Exacerbation Rate

    Time frame: Week 24

  2. To Evaluate the Effect of KB003 on Peak Expiratory Flow (PEF)

    Time frame: Week 24

  3. To Evaluate the Safety and Tolerability of KB003 as Measured by Frequency and Severity of AEs, Clinical Safety, Laboratory Abnormalities and Chest Radiographic Assessments

    Time frame: Week 24

Sponsors and collaborators

Lead sponsor

Humanigen, Inc.

Industry

Registry information

Official study title

A Phase 2, Double-blind, Placebo-controlled, Randomized Study to Evaluate the Safety, Tolerability, and Efficacy of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids

Acronym: KB003-04

Important dates

Study start
2012
Primary completion
2013
Study completion
2014
First posted
May 22, 2012
Registry last updated
Feb 2, 2015

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.